ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 34,006,567 shares, a drop of 3.7% from the February 15th total of 35,317,685 shares. Based on an average daily volume of 1,310,304 shares, the short-interest ratio is currently 26.0 days. Approximately 29.4% of the shares of the stock are sold short.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.34 on Monday. The stock has a market cap of $616.12, a PE ratio of -8.04 and a beta of 1.42. ZIOPHARM Oncology has a 52-week low of $3.33 and a 52-week high of $7.88.

How to Become a New Pot Stock Millionaire

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the prior year, the firm posted ($0.11) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. analysts anticipate that ZIOPHARM Oncology will post -0.58 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in ZIOP. Parametric Portfolio Associates LLC boosted its holdings in ZIOPHARM Oncology by 6.0% during the second quarter. Parametric Portfolio Associates LLC now owns 85,837 shares of the biotechnology company’s stock worth $534,000 after buying an additional 4,826 shares in the last quarter. State Street Corp raised its position in ZIOPHARM Oncology by 12.8% during the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after acquiring an additional 517,057 shares during the period. The Manufacturers Life Insurance Company raised its position in ZIOPHARM Oncology by 8.2% during the second quarter. The Manufacturers Life Insurance Company now owns 104,447 shares of the biotechnology company’s stock worth $649,000 after acquiring an additional 7,946 shares during the period. Adell Harriman & Carpenter Inc. acquired a new position in ZIOPHARM Oncology during the third quarter worth $141,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in ZIOPHARM Oncology by 933.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,918 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 32,444 shares during the period. 39.74% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages have recently commented on ZIOP. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. BidaskClub cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the stock a “buy” rating in a research note on Monday, March 5th. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.50.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/12/short-interest-in-ziopharm-oncology-inc-ziop-declines-by-3-7.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.